liveattenu
rna
viru
vaccin
efficaci
subject
revers
virul
among
rna
virus
replic
fidel
recogn
key
determin
virul
escap
antivir
therapi
increas
fidel
attenu
virus
coronaviru
replic
fidel
approxim
greater
rna
virus
mediat
exonucleas
activ
exon
like
function
rna
proofread
studi
demonstr
engin
inactiv
sarscov
exon
activ
result
stabl
mutat
phenotyp
profoundli
decreas
fidel
vivo
attenu
pathogenesi
young
age
immunocompromis
mous
model
human
sar
exon
inactiv
genotyp
mutat
phenotyp
stabl
revert
virul
even
serial
passag
longterm
persist
infect
vivo
approach
repres
strategi
potenti
broad
applic
stabl
attenu
coronavirus
possibl
rna
virus
approxim
emerg
infecti
diseas
identifi
origin
wildlif
past
pandem
clear
highli
pathogen
zoonos
signific
threat
global
human
health
econom
stabil
nation
secur
sever
acut
respiratori
syndrom
coronaviru
sarscov
swine
influenza
viru
caus
substanti
human
morbid
mortal
user
may
view
print
copi
download
text
datamin
content
document
purpos
academ
research
subject
alway
full
condit
use
st
centuri
like
influenza
coronavirus
cov
strong
histori
hostshift
crossspeci
transmiss
addit
emerg
sarscov
caus
mortal
age
popul
sever
human
cov
like
emerg
anim
reservoir
within
past
year
sudden
appear
new
respiratori
viral
pathogen
anim
dramat
underscor
need
novel
broadli
applic
platform
rapidli
ration
attenu
emerg
zoonos
especi
protect
vulner
popul
futur
outbreak
vaccin
long
histori
success
reduc
viral
diseas
burden
liveattenu
vaccin
ideal
elicit
balanc
innat
adapt
lifelong
protect
immun
respons
low
product
deliveri
cost
unfortun
broadli
applic
strategi
ration
design
liveattenu
viru
vaccin
remain
elus
vaccin
attenu
chemic
treatment
passag
revert
virul
result
diseas
outbreak
unvaccin
immunocompromis
moreov
precis
mechan
attenu
often
remain
unclear
thu
stabil
clearli
evalu
assur
rna
virus
encod
rnadepend
rna
polymeras
rdrp
lack
effici
proofread
capabl
result
high
error
rate
rang
mutat
per
site
per
round
replic
render
rna
virus
highli
vulner
lethal
mutagenesi
chemic
agent
high
mutat
rate
gener
consider
genom
divers
allow
rna
virus
rapidli
adapt
chang
environment
condit
host
increas
replic
fidel
shown
reduc
virul
polioviru
chikungunya
viru
propos
strategi
liveattenu
viru
design
coronavirus
cov
encod
largest
known
rna
viru
genom
kb
exceed
theoret
limit
viabl
rna
genom
size
cov
mutat
rate
calcul
occur
lower
frequenc
rna
virus
approach
mutat
per
site
per
round
replic
encod
viral
replicas
gene
contain
exoribonucleas
exon
deddh
exonucleas
superfamili
addit
cov
exon
homolog
present
member
nidoviral
order
whose
genom
kb
present
smaller
arterivirus
kb
suggest
exon
play
critic
role
genom
expans
vitro
exoribonucleas
activ
demonstr
recombin
sarscov
engin
recov
viabl
exon
inactiv
mutant
mous
hepat
viru
mhvexon
sarscov
sarsexon
mhvexon
sarsexon
inactiv
maintain
stabli
passag
vitro
exhibit
mutat
frequenc
compar
wildtyp
mhv
sarscov
thu
exon
play
critic
role
cov
rna
genom
replic
fidel
vitro
like
directli
mediat
stimul
proofread
function
previous
unknown
among
rna
virus
studi
use
stabl
lowfidel
mutat
phenotyp
sarscov
exon
mutant
platform
determin
whether
decreas
replic
fidel
could
use
broadli
applic
ration
design
strategi
liveattenu
vaccin
studi
evalu
impact
inactiv
rnaproofread
exonucleas
result
mutat
phenotyp
cov
replic
fit
pathogenesi
viru
stabil
passag
persist
vivo
efficaci
use
decreasedfidel
mutant
vaccin
studi
assess
potenti
gener
stabli
attenu
reversionresist
immunogen
strain
known
newli
identifi
cov
use
vaccin
immunocompet
immunocompromis
popul
exon
inactiv
mutat
engin
background
virul
mouseadapt
sarscov
mawt
yield
maexon
fig
b
mawt
caus
increas
mortal
acut
respiratori
distress
young
age
mous
model
maexon
compar
growth
experi
moi
pfu
cell
maexon
display
stabl
growth
defect
fig
place
direct
competit
maexon
clearli
less
fit
mawt
success
round
infect
supplementari
fig
b
maexon
genom
rna
level
roughli
equival
h
postinfect
pi
mawt
reduc
h
pi
maexon
genom
rna
level
approxim
mawt
level
h
pi
supplementari
fig
thu
data
suggest
maexon
abl
initi
establish
replic
effici
time
peak
rna
synthesi
h
impair
accumul
manifest
late
one
round
infect
amplifi
multipl
round
result
consist
accumul
defect
result
profoundli
increas
mutat
rate
see
discuss
rna
multipl
mawt
maexon
plaqu
sequenc
mawt
background
engin
exon
mutat
present
sequenc
maexon
clone
addit
maexon
accumul
greater
uniqu
mutat
mean
greater
mutat
frequenc
compar
mawt
p
fig
e
result
confirm
growth
replic
fidel
mutat
phenotyp
present
maexon
indistinguish
sarsexon
replic
cultur
assess
maexon
virul
young
age
femal
balbc
mice
infect
maexon
mawt
fig
young
mice
infect
mawt
exhibit
dosedepend
weight
loss
recoveri
fig
though
observ
dosedepend
differ
lung
titer
clearanc
pi
fig
contrast
young
mice
infect
maexon
exhibit
sign
clinic
diseas
high
dosedepend
lung
titer
rapidli
clear
pi
fig
b
next
maexon
mawt
compar
age
immunosenesc
mice
anim
infect
virus
exhibit
dosedepend
weight
loss
fig
lung
titer
equival
across
dose
maexon
mawt
infect
maexoninfect
mice
clear
viru
independ
inocul
dose
mawtinfect
mice
clear
viru
effici
highertit
infect
fig
addit
age
mice
infect
maexon
experienc
mortal
mawtinfect
mice
experienc
dosedepend
mortal
fig
describ
previous
littl
viru
detect
organ
experi
demonstr
maexon
attenu
young
age
diseas
model
compar
virul
mawt
diseas
symptom
present
less
pronounc
maexon
infect
mawt
infect
potenti
concern
liveattenu
vaccin
chanc
could
revert
virul
vivo
particularli
immunocompromis
individu
therefor
assess
whether
maexon
attenu
immunocompromis
mice
mawt
maexon
use
infect
young
rag
recombin
activ
gene
scid
sever
combin
immunodefici
signal
transduc
activ
transcript
mice
includ
background
control
balbc
respect
case
maexoninfect
anim
experienc
significantli
less
weight
loss
mawtinfect
mice
fig
c
p
see
supplementari
tabl
mice
experienc
notabl
weight
loss
due
maexon
infect
howev
experiment
morbid
threshold
pass
fig
contrast
mawtinfect
mice
die
moribund
pi
mawt
infect
lethal
control
mice
fig
c
previous
report
infect
mawt
maexon
persist
least
scid
mice
see
fig
potenti
allow
longitudin
cycl
replic
lowest
immun
barrier
emerg
mutat
confer
increas
fit
revers
virul
fidelitycompens
chang
test
viral
genom
viral
plaqu
grown
scid
lung
homogen
sequenc
fig
supplementari
tabl
mawt
total
consensu
mutat
identifi
nt
mutat
share
genom
result
distinct
mutat
synonym
nonsynonym
ns
maexon
engin
inactiv
mutat
maintain
contrast
mawt
maexon
plaqu
contain
total
mutat
distinct
ns
constitut
higher
total
mutat
accumul
compar
mawt
tabl
statist
determin
mutat
accumul
significantli
higher
maexoninfect
mice
region
p
addit
mean
accumul
increas
maexon
across
region
accumul
mutat
normal
per
kb
maexon
mutat
accumul
vs
region
significantli
differ
p
remain
significantli
increas
compar
mawt
p
new
mutat
identifi
three
maexon
plaqu
suggest
obligatori
consist
pattern
adapt
mutat
bia
preval
mutat
identifi
also
present
viral
stock
polymorph
howev
frequenc
viral
popul
remain
stabl
vitro
vivo
experi
balbc
scid
mice
supplementari
tabl
data
shown
result
exon
persist
infect
consist
result
passag
sarsexon
viru
cultur
ratio
accumul
uniqu
mutat
maexon
mawt
replic
scid
mice
rang
similar
measur
sexon
sarscov
cultur
test
resist
revers
virul
passag
vivo
subject
mawt
maexon
short
long
serial
passag
h
per
passag
respect
age
balbc
mice
fig
case
viral
titer
remain
stabl
passag
passag
fig
b
addit
viral
plaqu
phenotyp
preserv
exoninactiv
mutat
amino
acid
substitut
maintain
data
shown
contrast
mawt
titer
remain
stabl
serial
passag
mice
inocul
lung
homogen
die
passag
fig
interestingli
maexon
titer
remain
stabl
passag
mous
weight
decreas
infect
passag
fig
importantli
evid
gain
virul
serial
passag
maexon
pathogenesi
model
age
mice
infect
lung
homogen
final
passag
mice
infect
maexon
passag
lost
littl
weight
mawtinfect
anim
becam
moribund
fig
test
whether
maexon
persist
infect
could
result
phenotyp
revers
virul
virus
harvest
scid
mice
use
infect
young
balbc
mice
fig
mawtinfect
mice
exhibit
sign
morbid
weight
loss
hunch
postur
ruffl
fur
recov
contrast
maexoninfect
mice
exhibit
clinic
sign
ill
initi
infect
see
fig
addit
plaqu
contain
differ
mutat
subset
ident
attenu
upon
reinfect
balbc
mice
fig
result
demonstr
persist
infect
exon
mutat
phenotyp
revert
virul
despit
greatli
increas
mutat
rate
popul
divers
age
mice
mount
poor
product
immun
respons
sarscov
vaccin
remain
highli
suscept
sever
diseas
lethal
infect
thu
repres
sensit
measur
vaccin
efficaci
lethal
sarscov
infect
test
efficaci
maexon
mutant
possibl
vaccin
lethal
challeng
age
balbc
mice
vaccin
maexon
allow
recov
infect
mice
challeng
lethal
dose
mawt
fig
mockvaccin
mice
succumb
mawt
challeng
pi
high
lung
titer
fig
howev
mice
vaccin
maexon
protect
ill
fig
contrast
vaccin
platform
maexonvaccin
mice
detect
lung
titer
postchalleng
fig
addit
mice
vaccin
maexon
gener
high
level
neutral
antibodi
mean
reciproc
neutral
titer
fig
minim
neutral
titer
protect
sarscov
infect
mice
report
thu
even
singl
vaccin
maexon
provid
complet
protect
lethal
challeng
suscept
immunosenesc
mous
model
lethal
sarscov
infect
knowledg
maexon
viru
constitut
first
approach
sarscov
immun
fulli
protect
clinic
diseas
replic
age
mous
model
liveattenu
vaccin
profoundli
reduc
global
diseas
burden
associ
viral
infect
ie
measl
mump
rubella
polio
yellow
fever
chickenpox
liveattenu
vaccin
often
result
longlast
protect
immun
singl
administr
addit
often
less
expens
produc
rapidli
make
prime
candid
firstrespons
strategi
epidem
emerg
virus
howev
liveattenu
vaccin
carri
sever
risk
includ
primari
secondari
revers
virul
phenotyp
fact
attenu
phenotyp
encount
natur
select
pressur
revers
caus
outbreak
diseas
unvaccin
popul
rna
viru
replic
fidel
evolv
balanc
genom
divers
stabil
therefor
inactiv
enzym
respons
highfidel
replic
could
theoret
drive
viru
toward
instabl
deleteri
mutat
divers
like
result
decreas
fit
complex
environ
observ
vitro
fig
supplementari
fig
possibl
may
serv
function
viral
rna
synthesi
howev
global
impair
viral
rna
synthesi
alon
explain
vitro
result
vivo
attenu
phenotyp
possibl
fulli
separ
defect
due
increas
mutat
load
result
replic
defect
observ
like
contribut
phenotyp
howev
result
consist
hypothesi
stabl
evolv
defect
result
mutat
phenotyp
irrevoc
attenu
maexon
defect
could
includ
mutat
impair
termin
translat
replic
transcript
mutat
impair
abolish
protein
function
chang
rna
polymeras
process
presenc
inactiv
proofread
exonucleas
combin
impair
may
profoundli
manifest
cov
exon
mutant
high
number
accumul
mutat
per
genom
unpreced
among
viral
mutat
strain
inde
phenotyp
similar
report
model
system
inactiv
exonucleas
human
mitochondri
dna
polymeras
pol
bacteriophag
dna
polymeras
pol
studi
loss
proofread
associ
impair
polymeras
activ
manner
like
causal
imposs
uncoupl
character
decreas
speed
increas
templat
dissoci
restrict
access
nucleotid
polymeras
activ
site
cov
high
level
iter
amplif
genom
subgenom
rna
would
acceler
deleteri
process
provid
aberr
templat
loss
exon
proofread
would
continu
gener
new
potenti
attenu
allel
defect
genom
would
reduc
genom
fit
supplementari
fig
risk
primari
secondari
revers
virul
studi
demonstr
maexon
attenu
mice
mutant
clear
rapidli
presenc
adapt
immun
respons
experi
recapitul
mani
phenotyp
observ
age
immunocompromis
human
popul
addit
test
primat
necessari
scid
persist
infect
experi
verifi
accumul
mutat
across
genom
without
evid
select
either
phenotyp
virulenceenhanc
allel
primari
genotyp
revers
virus
harvest
passag
remain
avirul
support
conclus
select
virul
occur
select
outcompet
gradual
accumul
attenu
mutat
individu
genom
popul
mutat
swarm
mutant
unabl
gener
select
either
fastgrow
slowclear
virus
also
virul
surprisingli
limit
number
polymorph
supplementari
tabl
identifi
maexon
viru
stock
use
subsequ
experi
virus
without
mutat
fulli
attenu
vivo
fig
mutat
also
maintain
lung
frequenc
viru
stock
suggest
select
passag
vivo
supplementari
tabl
thu
singl
mutat
polymorph
could
clearli
link
viral
attenu
except
exon
inactiv
importantli
shown
maexon
vaccin
complet
protect
replic
lethal
challeng
age
balbc
mice
sarscov
mous
pathogenesi
model
captur
sever
clinic
diseas
outcom
human
infect
addit
neutral
titer
equival
superior
twodos
alphaviru
replicon
glycoprotein
vaccin
kill
vaccin
contain
alum
addit
advantag
protect
viru
replic
clinic
diseas
liveattenu
vaccin
must
possess
two
characterist
asid
capac
elicit
protect
immun
respons
resist
primari
revers
stabl
attenu
secondari
site
demonstr
maexon
possess
characterist
circumst
engin
inactiv
mutat
maintain
indic
exonucleas
activ
critic
viru
life
cycl
chang
present
substanti
barrier
primari
revers
passag
experi
suggest
viru
lack
redund
complement
mechan
fulli
restor
loss
exon
activ
final
maexon
harvest
persist
infect
scid
mice
retain
attenu
phenotyp
reinocul
mice
suggest
persist
select
virul
futur
studi
address
whether
addit
modif
could
serv
enhanc
stabil
attenu
phenotyp
reduc
likelihood
gain
function
homolog
recombin
introduct
exon
inactiv
trsrewir
background
could
increas
resist
revers
inactiv
put
viral
proofread
compon
pursuit
stabl
vaccin
constitut
paradigm
high
potenti
broadli
applic
member
nidoviral
exonucleas
activ
time
metagenom
studi
inform
us
likelihood
futur
viral
emerg
event
virus
potenti
afflict
human
popul
much
sarscov
design
readi
implement
attenu
strategi
rapidli
appli
emerg
cov
repres
signific
advanc
preserv
public
health
data
also
encourag
pursuit
fidelityimpair
mutat
replicas
protein
rna
virus
potenti
target
use
cov
vaccin
vector
ration
vaccin
design
sarscov
plasmid
construct
restrict
digest
ligat
exist
sar
dexoni
sar
dmouseadapt
plasmid
briefli
plasmid
restrict
digest
bstb
xba
enzym
follow
treatment
digest
sar
dexoni
plasmid
antarct
phosphatas
new
england
biolab
ipswitch
usa
fragment
isol
purifi
ligat
togeth
use
dna
ligas
overnight
describ
previous
coloni
screen
proper
insert
size
restrict
digest
electrophoresi
presenc
appropri
mutat
verifi
sequenc
viru
contain
exoni
inactiv
mouseadapt
mutat
within
viral
code
sequenc
produc
use
infecti
cdna
assembl
strategi
sarscov
previous
describ
exon
virus
kept
low
passag
one
passag
past
viru
rescu
minim
accumul
mutat
cell
cultur
studi
equival
lowpassag
mawt
viru
use
comparison
mawt
maexon
virus
grown
vero
cell
moi
pfu
cell
vitro
experi
except
genom
rna
quantif
experi
perform
moi
pfu
cell
passag
seri
growth
experi
perform
viral
titer
determin
describ
vero
cell
plate
cell
well
plate
cell
infect
moi
combin
mawt
maexon
proport
favor
either
maexon
mawt
incub
h
h
aliquot
supernat
pass
fresh
plate
vero
cell
five
total
success
passag
infect
monolay
harvest
trizol
invitrogen
grand
island
ny
usa
passag
complet
rna
purifi
accord
manufactur
protocol
firststrand
cdna
gener
describ
pcr
product
produc
use
primer
supplementari
tabl
presenc
singleband
pcr
product
verifi
agaros
gel
electrophoresi
yield
calcul
spectrometri
ng
product
restrictiondigest
use
bsrf
cut
engin
mutat
site
cut
correspond
mawt
sequenc
digest
product
resolv
agaros
gel
normal
rel
percentag
mawt
vs
exonma
digest
product
calcul
use
imagej
http
rsbwebnihgovij
vero
cell
infect
either
mawt
maexon
moi
pfu
cell
h
pi
rna
harvest
trizol
isol
accord
manufactur
protocol
firststrand
cdna
gener
realtim
pcr
perform
assess
genom
rna
use
primer
forward
revers
cdna
normal
use
gapdh
primer
forward
revers
normal
result
compar
ratio
maexon
mawt
genom
use
method
mice
weigh
daili
certain
day
specifi
experi
subset
mice
group
sacrif
lung
harvest
viru
titer
mice
drop
initi
mass
moribund
sacrif
schedul
timepoint
serial
passag
inocul
passag
subsequ
passag
inocul
clarifi
lung
homogen
lung
homogen
ml
pb
previou
passag
experi
use
n
mice
per
viru
per
dosag
condit
applic
per
timepoint
except
experi
use
immunocompromis
mice
n
lung
harvest
viru
titer
weigh
homogen
ml
pb
rpm
magnalys
roch
basel
switzerland
viru
titer
determin
plaqu
assay
vero
cell
previous
describ
mous
sera
heatinactiv
min
serial
dilut
pb
volum
next
pb
contain
lowconcentr
mawt
pfu
highconcentr
mawt
pfu
ad
serum
dilut
virusserum
mixtur
incub
min
follow
incub
viru
titer
mixtur
determin
plaqu
assay
describ
final
calcul
plaqu
reduct
neutral
titer
prnt
valu
serum
dilut
plaqu
format
reduc
rel
viru
stock
treat
serum
determin
sequenc
viral
genom
present
scid
mous
lung
infect
plaqu
isol
scid
mous
lung
sampl
describ
briefli
individu
wellresolv
viral
plaqu
visibl
harvest
collect
agaros
plug
use
pipett
tip
agaros
plug
drop
ml
pb
allow
diffus
h
appli
confluent
monolay
vero
cell
flask
incub
h
infect
cell
monolay
harvest
ml
trizol
firststrand
cdna
gener
describ
amplicon
viral
genom
gener
follow
whole
genom
sequenc
amplicon
partial
genom
sequenc
amplicon
ag
x
primer
pair
indic
supplementari
tabl
use
pcr
reaction
use
phusion
polymeras
new
england
biolab
five
microlit
pcr
reaction
electrophores
agaros
gel
verifi
presenc
correctli
size
amplicon
pcr
product
purifi
use
qiagen
pcr
purif
kit
qiagen
valencia
ca
usa
amplicon
sequenc
use
correspond
primer
set
amplicon
indic
supplementari
tabl
sequenc
result
analyz
use
geneiou
pro
biomatt
auckland
new
zealand
serial
cloner
serialbas
http
serialbasicsfreefrhomehomehtml
statist
analys
perform
use
mannwhitney
u
test
http
eleganssomvcueduleonstatsutesthtml
signific
set
p
color
follow
blue
synonym
uniqu
one
sequenc
light
blue
synonym
present
three
sequenc
red
nonsynonym
uniqu
one
sequenc
green
synonym
present
two
sequenc
purpl
inactiv
mutat
mutat
alter
size
orf
indic
red
symbol
delet
red
stop
codon
genom
size
orf
nsp
boundari
mutat
marker
placement
approxim
mean
reciproc
dilut
indic
bar
group
limit
detect
assay
indic
dash
line
